Drugs / CoQ10
CoQ10
also known as
BPM31510 · ubiquinone · Coenzyme Q10 · API 31510 · ubiquinol · Qred · reduced coenzyme Q10 · Ubidecarenone
Trials 22
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06419335 | Jul 2024 → Apr 2026 overdue | Crohn disease | University of Pennsylvania | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03956017 | Aug 2013 → Aug 2022 | — | Minneapolis Veterans Affairs Medical Center | Unknown | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT03020602 | Jan 2017 → Apr 2019 | brain astrocytoma, gliosarcoma | Seema Nagpal | Completed | No outcome recorded |
| Phase 1 | NCT03002935 | Jan → Mar 2017 | — | BPGbio | Completed | No outcome recorded |
| Phase 1 | NCT02793960 | Aug 2016 → Aug 2019 | epidermolysis bullosa | Shasa Hu | Completed | No outcome recorded |
| Phase 1 | NCT00976131 | Sep 2009 → Sep 2012 | breast cancer | Columbia University | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00652080 | Jun 2008 → Jan 2010 | squamous cell carcinoma | BPGbio | Completed | No outcome recorded |
| Phase 1/2 | NCT00604890 | Mar 2008 → Jan 2010 | basal cell carcinoma | BPGbio | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT06555575 | Jan 2025 → Sep 2026 overdue | — | Trio Fertility | Recruiting | No outcome recorded |
| Phase 2 | NCT04752813 | Aug 2022 → Aug 2026 overdue | glioblastoma | BPGbio | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02650804 | Jul 2016 → Jun 2019 | malignant pancreatic neoplasm | BPGbio | Completed | No outcome recorded |
| Phase 2 | NCT02062034 | Feb 2011 → Nov 2013 | diabetic retinopathy, type 2 diabetes mellitus | University of Guadalajara | Completed | No outcome recorded |
| Phase 2 | NCT00920699 | Feb 2010 → Mar 2012 | Huntington disease | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT00605709 | Mar → Jul 2008 | skin squamous cell carcinoma | BPGbio | Withdrawn | No outcome recorded |
| Phase 2 | NCT00076492 | Jan 2004 → Sep 2005 | Parkinson disease | University of Rochester | Completed | No outcome recorded |
| Phase 2 | NCT00703482 | May 2003 → Sep 2004 | — | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00532571 | Jan 2004 → Sep 2005 | progressive supranuclear palsy | Lahey Clinic | Completed | No outcome recorded |
| Phase not applicable5 trials · 1 missed | ||||||
| — | NCT06373848 | Mar → May 2024 overdue | chronic periodontitis | Islamic Azad University, Sanandaj | Enrolling by invitation | No outcome recorded |
| — | NCT06358963 | Feb → Apr 2024 | periodontal disorder | Amirhossein Farahmand | Unknown | No outcome recorded |
| — | NCT05653895 | Dec 2022 → Dec 2023 | polycystic ovary syndrome | Khyber Medical University Peshawar | Completed | No outcome recorded |
| — | NCT04487652 | Sep 2020 → Aug 2022 | gingival recession | University of Bern | Completed | Missed primary |
| — | NCT02218476 | Sep 2013 → Sep 2016 | — | Maimónides Biomedical Research Institute of Córdoba | Unknown | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 0 | NCT04999488 Comparator | Dec 2023 → Dec 2024 | muscular atrophy | AdventHealth Translational Research Institute | Withdrawn | No outcome recorded |
| Phase 1 | NCT02486055 Comparator | Nov 2015 → Jan 2016 | — | BPGbio | Completed | No outcome recorded |
| Phase 2 | NCT06962657 Comparator | May 2026 → Oct 2028 expected | — | University of California, San Diego | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06620523 Comparator | Jul 2024 → Jun 2027 expected | coronary artery disorder, kidney failure | George Washington University | Recruiting | No outcome recorded |
| Phase 3 | NCT06515184 Comparator | Sep 2024 → Dec 2027 expected | mitochondrial respiratory chain complex deficiency, persian gulf syndrome | University of California, San Diego | Recruiting | No outcome recorded |
| — | NCT00893724 Comparator | Jun 2009 → Aug 2011 | diabetic macular edema, wet macular degeneration | Mid-Atlantic Retina Consultations, Inc. | Unknown | No outcome recorded |
Press releases naming this drug 22 releases
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 30 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COQ10 | “It has been shown that in an aged mouse model, administration of CoQ10 (ubiquinone) results in improved mitochondrial energy production, more healthy embryos and more live-born pups.” NCT06555575 ↗15“Co Q10 or ubiquinone is an essential mitochondrial co-factor that has a critical role as a component of the electron transport chain and free radical scavenger.” NCT06620523 ↗ “Coenzyme Q10 (CoQ10) a lipid soluble coenzyme which is an important component of the inner membrane of mitochondria.” NCT05653895 ↗ |
| Known as | API 31510 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00652080 ↗ |
| Known as | BPM31510 | “ubidecarenone injectable nanosuspension (BPM31510)” NCT03020602 ↗ |
| Known as | Coenzyme Q10 | “The purpose of this study is to assess whether a high quality preparation of ubiquinone (coenzyme Q10) benefits symptoms, function, and quality of life in veterans with Gulf...” NCT06515184 ↗4“Coenzyme Q10 (CoQ10) or ubiquinone is one of a cell's most important electron carriers during oxidative phosphorylation and many other cellular processes.” PMID 38990401 ↗ Jul 2024 “Coenzyme Q10 (CoQ10) a lipid soluble coenzyme which is an important component of the inner membrane of mitochondria.” NCT05653895 ↗ “daily 1200 mg of Co enzyme Q10 (CoQ10) and 1000 mg of Glutathione (GSH)” NCT06620523 ↗ “Quantification of CoQ10 (Coenzyme Q10)” NCT02218476 ↗ |
| Known as | Qred | “in vivo ubiquinol (reduced coenzyme Q10 [Qred]) supplementation” PMID 28684614 ↗ Jul 2017 |
| Known as | reduced coenzyme Q10 | “in vivo ubiquinol (reduced coenzyme Q10 [Qred]) supplementation” PMID 28684614 ↗ Jul 2017 |
| Known as | Ubidecarenone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03020602 ↗ |
| Known as | ubiquinol | “CoQ10 is available as ubiquinol (reduced form) or ubiquinone (oxidized form)” NCT06620523 ↗1“in vivo ubiquinol (reduced coenzyme Q10 [Qred]) supplementation” PMID 28684614 ↗ Jul 2017 |
| Known as | ubiquinone | “The purpose of this study is to assess whether a high quality preparation of ubiquinone (coenzyme Q10) benefits symptoms, function, and quality of life in veterans with Gulf...” NCT06515184 ↗6“Co Q10 or ubiquinone is an essential mitochondrial co-factor that has a critical role as a component of the electron transport chain and free radical scavenger.” NCT06620523 ↗ “Coenzyme Q10 (CoQ10) or ubiquinone is one of a cell's most important electron carriers during oxidative phosphorylation and many other cellular processes.” PMID 38990401 ↗ Jul 2024 |
| Modality | Other / unclassified | “Coenzyme Q10 is a fat soluble antioxidant dietary supplement” NCT00976131 ↗ |
| Route | Topical | “Topical treatment 3% active cream applied to the lesion” NCT00604890 ↗ |